Article
As EULAR2026 comes to a close, practical learnings take precedence as clinicians head back to their clinics. Among them, the 2026 EULAR Update on Imaging Recommendations in SpA stands out.
All News
Article
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Article
The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
Article
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Dr. John Cush
Tweet
Long-term Cancer Risk with Targeted Therapy in SpA
Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London
https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK
Dr. John Cush
Tweet
True or False: Current guidelines for peripheral SpA recommend initiating treatment with TNF inhibitors before trying NSAIDs or conventional synthetic DMARDs. See if you got it right in this week's RheumIQ quiz at https://t.co/6uiqJjYUVo https://t.co/9hHFjaGUdt
Dr. John Cush
Tweet
New: Classification Criteria and Recommendations in SpA
ASAS and SPARTAN have updated their key classification criteria for axSpA. EULAR has also recently revised its recommendations on the role of imaging in the diagnosis and clinical management of SpA. https://t.co/YOWfwTkbqp
Dr. John Cush
Tweet
Improving Referrals for Inflammatory Arthritis
Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London
https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj
Dr. John Cush
Tweet
Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA
The approach to treating peripheral SpA has remained the same for a long time. The guidelines recommend starting with NSAIDs, escalating to conventional synthetic DMARDs, typically sulfasalazine or methotrexate, and https://t.co/iEqzp6FStv
Dr. John Cush
Tweet
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Nelly ZIADE 🍀
Tweet
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
Jiha Lee
Tweet
Patient-initiated telemedicine follow-up cut rheumatology visits by 25% in stable #SpA, but not equally for everyone. Reductions were greatest in men, axSpA, bDMARD users, and the oldest patients (64+, 34% fewer visits). Patient-centered care delivery @RheumNow #EULAR2026 POS1345
Dr. John Cush
Tweet
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush
Tweet
Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
Nelly ZIADE 🍀
Tweet
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow
Nelly ZIADE 🍀
Tweet
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype
Results from the Spanish REGISPON-3
POS1352
#EULAR2026 @RheumNow https://t.co/XicguAdXJ1
Nelly ZIADE 🍀
Tweet
How many patients with IBD have axSpA?
POS1338 #EULAR2026 @RheumNow
⬇️⬇️⬇️ https://t.co/29qkrCnDYz
Nelly ZIADE 🍀
Tweet
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?
Yes! POS 1347
Multicenter randomised open-label trial
N=56
#EULAR2026 @RheumNow https://t.co/kP7ropPkpC
Nelly ZIADE 🍀
Tweet
What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?
Data from 194 patients from the SELECT-AXIS2 RCT:
▶️ Remission maintained in 1/4 at48 weeks
POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
Md Yuzaiful Md Yusof
Tweet
#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN
